Literature DB >> 31808069

The effect of metal salts on aerosol performance of spray dried carrier-free formulations of levofloxacin.

Ahmadreza Barazesh1, Kambiz Gilani2,3, Mohammadreza Rouini4, Mohammad Ali Barghi5.   

Abstract

PURPOSE: Metal salts are used in formulation of dry powder inhalers (DPIs) for different purposes. Recently the role of these salts in production of small, dense but highly dispersible particles has emerged. In this study the effect of some such salts on dispersibility and respirability of spray dried levofloxacin formulations was evaluated in normal and reduced inhalation air flow or by increasing powder filling in capsules.
METHODS: levofloxacin was co-spray dried with different concentrations of common metal chlorides (NaCl, KCl, CaCl2 and MgCl2) either with or without leucine as dispersibility enhancer. Particle size, moisture, morphology, triboelectrification tendency and fine particle fraction (FPF) of resulting powders were evaluated. In addition, the effect of these salts and leucine on dispersibility of resulting powders in reduced air flow rate and increased capsule filling mass were evaluated.
RESULTS: Presence of higher tested concentrations of divalent cations increased water content, and reduced FPF significantly. Addition of leucine reduced water content and electrostatic charge, increased particle size and FPF and improved spray drying yield significantly. Lower concentrations of salts did not affect FPF of leucine containing powders significantly, but presence of 2.5% NaCl or MgCl2 preserved the dispersibility in higher capsule fillings. A 2.5% concentration of NaCl in such formulations preserved dispersibility in lower air flows.
CONCLUSION: Higher amounts of divalent salts increases triboelectrification and moisture absorption, and reduces FPF. Lower concentrations of NaCl could not improve FPF of leucine containing formulations significantly, but preserves dispersibility in low air flows and high capsule fillings. Graphical abstract.

Entities:  

Keywords:  Dry powder inhaler; Leucine; Levofloxacin; Metal salts; Particle engineering; Spray drying

Mesh:

Substances:

Year:  2019        PMID: 31808069      PMCID: PMC7214557          DOI: 10.1007/s40199-019-00317-9

Source DB:  PubMed          Journal:  Daru        ISSN: 1560-8115            Impact factor:   3.117


  27 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

2.  Spray dried amikacin powder for inhalation in cystic fibrosis patients: a quality by design approach for product construction.

Authors:  Silvia Belotti; Alessandra Rossi; Paolo Colombo; Ruggero Bettini; Dimitrios Rekkas; Stavros Politis; Gaia Colombo; Anna Giulia Balducci; Francesca Buttini
Journal:  Int J Pharm       Date:  2014-06-02       Impact factor: 5.875

Review 3.  Dry powders for oral inhalation free of lactose carrier particles.

Authors:  Anne Marie Healy; Maria Inês Amaro; Krzysztof J Paluch; Lidia Tajber
Journal:  Adv Drug Deliv Rev       Date:  2014-04-13       Impact factor: 15.470

4.  Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.

Authors:  Heino Stass; Boris Weimann; Johannes Nagelschmitz; Claudia Rolinck-Werninghaus; Doris Staab
Journal:  Clin Ther       Date:  2013-09-18       Impact factor: 3.393

Review 5.  Inhaled formulations and pulmonary drug delivery systems for respiratory infections.

Authors:  Qi Tony Zhou; Sharon Shui Yee Leung; Patricia Tang; Thaigarajan Parumasivam; Zhi Hui Loh; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2014-10-24       Impact factor: 15.470

6.  Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin.

Authors:  Ahmadreza Barazesh; Kambiz Gilani; Mohammadreza Rouini; Mohammad Ali Barghi
Journal:  Eur J Pharm Sci       Date:  2018-03-02       Impact factor: 4.384

7.  Towards a more desirable dry powder inhaler formulation: large spray-dried mannitol microspheres outperform small microspheres.

Authors:  Waseem Kaialy; Tariq Hussain; Amjad Alhalaweh; Ali Nokhodchi
Journal:  Pharm Res       Date:  2013-08-06       Impact factor: 4.200

8.  The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.

Authors:  R Price; P M Young; S Edge; J N Staniforth
Journal:  Int J Pharm       Date:  2002-10-10       Impact factor: 5.875

9.  Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.

Authors:  Gabrielle Pilcer; Véronique De Bueger; Karl Traina; Hamidou Traore; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Int J Pharm       Date:  2013-04-30       Impact factor: 5.875

10.  Population pharmacokinetics of inhaled tobramycin powder in cystic fibrosis patients.

Authors:  L Ting; S Aksenov; S G Bhansali; R Ramakrishna; P Tang; D E Geller
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.